Outcome measures for primary Sjögren's syndrome: A comprehensive review
- 8 January 2014
- journal article
- review article
- Published by Elsevier BV in Journal of Autoimmunity
- Vol. 51, 51-56
- https://doi.org/10.1016/j.jaut.2013.12.010
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary Sjögren’s Syndrome. Data at Enrollment in the Prospective ASSESS CohortPLOS ONE, 2013
- Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registryAnnals Of The Rheumatic Diseases, 2012
- BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glandsRheumatology, 2012
- Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of responseAnnals Of The Rheumatic Diseases, 2012
- Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndromeAnnals Of The Rheumatic Diseases, 2011
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialThe Lancet, 2011
- Novel evidence‐based systemic lupus erythematosus responder indexArthritis Care & Research, 2009
- EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndromeAnnals Of The Rheumatic Diseases, 2009
- Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndromeAnnals Of The Rheumatic Diseases, 2007
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992